Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. | Togun et al. AIDS Research and Therapy 2011 8 24 http www.aidsrestherapy.eom content 8 1 24 AIDS RESEARCH AND THERAPY RESEARCH Open Access Pre-treatment mortality and loss-to-follow-up in HIV-1 HIV-2 and HIV-1 HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia West Africa -I- -I- 1 2 3 1 1 1.4 1.5 Toyin Togun Ingrid Peterson Shabbar Jaffar Francis Oko Uduak Okomo Kevin Peterson and Assan Jaye Abstract Background High early mortality rate among HIV infected patients following initiation of antiretroviral therapy ART in resource limited settings may indicate high pre-treatment mortality among ART-eligible patients. There is dearth of data on pre-treatment mortality in ART programmes in sub-Sahara Africa. This study aims to determine pre-treatment mortality rate and predictors of pre-treatment mortality among ART-eligible adult patients in a West Africa clinic-based cohort. Methods All HIV-infected patients aged 15 years or older eligible for ART between June 2004 and September 2009 were included in the analysis. Assessment for eligibility was based on the Gambia ART guideline. Survival following ART-eligibility was determined by Kaplan-Meier estimates and predictors of pre-treatment mortality determined by Cox proportional hazard models. Result Overall 790 patients were assessed as eligible for ART based on their clinical and or immunological status among whom 510 64.6 started treatment 26 3.3 requested transfer to another health facility 136 17.2 and 118 14.9 were lost to follow-up and died respectively without starting ART. ART-eligible patients who died or were lost to follow-up were more likely to be male or to have a CD4 T-cell count 100 cells gL while patients in WHO clinical stage 3 or 4 were more likely to die without starting treatment. The overall pretreatment mortality rate was 21.9 deaths per 100 person-years 95 CI 18.3 - 26.2 and the rate for the composite end point of death or loss to follow-up was 47.1 per 100 person-years
